Cargando…

The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study

Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants due to immune escape is challenging for the global response to the pandemic. We estimated the Omicron reinfection prevalence among people who had a previous SARS-CoV-2 infection in Shanghai, China. We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Chuchu, Zhang, Ge, Zhang, Anran, Xin, Hualei, Wu, Kang, Li, Zhongjie, Jia, Yilin, Hao, Lipeng, Xue, Caoyi, Wang, Yuanping, Xu, Hongmei, Zhu, Weiping, Zhou, Yixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386598/
https://www.ncbi.nlm.nih.gov/pubmed/37514962
http://dx.doi.org/10.3390/vaccines11071146
_version_ 1785081707263688704
author Ye, Chuchu
Zhang, Ge
Zhang, Anran
Xin, Hualei
Wu, Kang
Li, Zhongjie
Jia, Yilin
Hao, Lipeng
Xue, Caoyi
Wang, Yuanping
Xu, Hongmei
Zhu, Weiping
Zhou, Yixin
author_facet Ye, Chuchu
Zhang, Ge
Zhang, Anran
Xin, Hualei
Wu, Kang
Li, Zhongjie
Jia, Yilin
Hao, Lipeng
Xue, Caoyi
Wang, Yuanping
Xu, Hongmei
Zhu, Weiping
Zhou, Yixin
author_sort Ye, Chuchu
collection PubMed
description Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants due to immune escape is challenging for the global response to the pandemic. We estimated the Omicron reinfection prevalence among people who had a previous SARS-CoV-2 infection in Shanghai, China. We conducted a telephone survey in December 2022 with those who had previously been infected with Omicron between March and May 2022. Information on their demographics, coronavirus disease 2019 (COVID-19) testing, and vaccination history was collected. The overall and subgroup reinfection rates were estimated and compared. Among the 1981 respondents who were infected between March and May 2022, 260 had positive nucleic acid or rapid antigen tests in December 2022, with an estimated reinfection rate of 13.1% (95% confidence interval [95% CI]: 11.6–14.6). The reinfection rate for those who had a booster vaccination was 11.4% (95% CI: 9.2–13.7), which was significantly lower than that for those with an incomplete vaccination series (15.2%, 95% CI: 12.3–18.1) (adjusted odds ratio [aOR]: 0.579; 95% CI: 0.412–0.813). Reinfection with the Omicron variant was lower among individuals with a previous SARS-CoV-2 infection and those who had a booster vaccination, suggesting that hybrid immunity may offer protection against reinfection with Omicron sublineages.
format Online
Article
Text
id pubmed-10386598
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103865982023-07-30 The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study Ye, Chuchu Zhang, Ge Zhang, Anran Xin, Hualei Wu, Kang Li, Zhongjie Jia, Yilin Hao, Lipeng Xue, Caoyi Wang, Yuanping Xu, Hongmei Zhu, Weiping Zhou, Yixin Vaccines (Basel) Article Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants due to immune escape is challenging for the global response to the pandemic. We estimated the Omicron reinfection prevalence among people who had a previous SARS-CoV-2 infection in Shanghai, China. We conducted a telephone survey in December 2022 with those who had previously been infected with Omicron between March and May 2022. Information on their demographics, coronavirus disease 2019 (COVID-19) testing, and vaccination history was collected. The overall and subgroup reinfection rates were estimated and compared. Among the 1981 respondents who were infected between March and May 2022, 260 had positive nucleic acid or rapid antigen tests in December 2022, with an estimated reinfection rate of 13.1% (95% confidence interval [95% CI]: 11.6–14.6). The reinfection rate for those who had a booster vaccination was 11.4% (95% CI: 9.2–13.7), which was significantly lower than that for those with an incomplete vaccination series (15.2%, 95% CI: 12.3–18.1) (adjusted odds ratio [aOR]: 0.579; 95% CI: 0.412–0.813). Reinfection with the Omicron variant was lower among individuals with a previous SARS-CoV-2 infection and those who had a booster vaccination, suggesting that hybrid immunity may offer protection against reinfection with Omicron sublineages. MDPI 2023-06-25 /pmc/articles/PMC10386598/ /pubmed/37514962 http://dx.doi.org/10.3390/vaccines11071146 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ye, Chuchu
Zhang, Ge
Zhang, Anran
Xin, Hualei
Wu, Kang
Li, Zhongjie
Jia, Yilin
Hao, Lipeng
Xue, Caoyi
Wang, Yuanping
Xu, Hongmei
Zhu, Weiping
Zhou, Yixin
The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study
title The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study
title_full The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study
title_fullStr The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study
title_full_unstemmed The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study
title_short The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study
title_sort omicron variant reinfection risk among individuals with a previous sars-cov-2 infection within one year in shanghai, china: a cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386598/
https://www.ncbi.nlm.nih.gov/pubmed/37514962
http://dx.doi.org/10.3390/vaccines11071146
work_keys_str_mv AT yechuchu theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT zhangge theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT zhanganran theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT xinhualei theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT wukang theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT lizhongjie theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT jiayilin theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT haolipeng theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT xuecaoyi theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT wangyuanping theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT xuhongmei theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT zhuweiping theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT zhouyixin theomicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT yechuchu omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT zhangge omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT zhanganran omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT xinhualei omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT wukang omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT lizhongjie omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT jiayilin omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT haolipeng omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT xuecaoyi omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT wangyuanping omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT xuhongmei omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT zhuweiping omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy
AT zhouyixin omicronvariantreinfectionriskamongindividualswithaprevioussarscov2infectionwithinoneyearinshanghaichinaacrosssectionalstudy